人扁桃体细胞干扰素治疗单疱角膜炎(37例39眼临床疗效观察)

Treatment of Herpes Simplex Corneal Ulcer by Interferon

单疱病毒角膜炎易于复发,已成为常见的严重致盲眼病。目前使用的抗单疱药物均有一定的毒性,加上耐药病毒株的产生,因而降低了它们的临床使用价值。人们从实验研究知道,人类炮疹病毒对人干扰素极为敏感。干扰素由于抗病毒谱广而毒性小,成为颇受注意的一种新药。自从Jones(1962)报告用猴干扰素治疗人单疱角膜炎有效以后,国外陆续有文献报告用人白细胞干扰素治疗单疱角膜炎的研究结果。国内近年也开展干扰素的研制及临床治疗单疱角膜炎的观察,但报告尚少。现将我院与广州医药卫生研究所合作用人扁桃体细胞干扰素于1982一1983年治疗观察的37例39眼单疱角膜炎结果报告如下;

39 eyes suffered from herpes simplex corneal ulcer with characteristic clinical appearance were treated by subconjunctive injection of human ton sil leukocyte interferon. The dose was 50,000-400,000 units once daily. 36 eyes(92.3%)were cured, 1 eye was improved, but 2 eyes were not.There was no difference in statistics between the interferon group and control group. The latter was treated by topical drops of both 0.1% IDU solution and 0.05% C C solution. However, the cure time of the interferon group was obviously much shorter than that of the contorl group. Furthermore, those cases which failed with IDU and CC solution were cured by interferon. This result indicated that therapy using 50,000 units interferonaolmini-ste ed by subconjunctive injection once daily was effective in the treatment of herpes simplex corneal ulcers of various types.It seems that there is no need to use the specially high dose of interferon.The administration of subconjunctive injection of outpatient can solve the proplem that the interferon preparation needs refrigeration.This administration can save the interferon which is expensive and not easily available at present. Moreover, this administration of interferon can be sure to have benefit to some childhood patients who refuse topic drops.